Browsing Category

Production to Prescription Podcast

19 posts

DCAT Value Chain Insights’ original podcast, Production to Prescription, featuring thought leaders with expert views on the major happenings impacting the global bio/pharmaceutical manufacturing value chain and industry performance.

Keep pace with a changing marketplace and hear from industry experts on the issues and trends that need to be on your radar.

For the 2026 podcast schedule, click here.

For the 2027 podcast schedule, click here.

See below for the latest episode or get through:

  • Apple Podcast
  • Spotify Podcast

Protacs & Molecular Glue Degraders: Market Contenders or Not?
By

By
New drug classes–proteolysis-targeting chimeras (PROTACs) and molecular glue degraders–are potentially a new source of product innovation for small-molecule drugs in their ability to reach previously “undruggable” drug targets. There have…

Biomanufacturing: Capacity Trends & CDMO Insights
By

By
Sponsored by Lonza AG What is the state-of-the state for biomanufacturing (drug substance) in terms of industry capacity utilization, in-sourced/outsourced activity, and technology drivers? Is capacity in line with demand…

Beyond ADCs: Next-Generation Drug Conjugates
By

By
Sponsored by Lonza AG Next-generation complex conjugates, such as peptide conjugates, radioconjugates, ligand-conjugated antisense medicines, and small-molecule drug conjugates, are expected to outpace growth comparative to antibody drug conjugates (ADCs),…

New Excipient Products: Are They Coming?
By

By
Innovation in excipients is important to optimize a drug formulation, but there are barriers to innovation, including regulatory barriers, which excipient manufacturers and users are seeking to address. Providing the…

Pipeline Potential: Small-Molecule Drugs
By

By
New drug classes–proteolysis-targeting chimeras (PROTACs) and molecular glue degraders–are potentially a new source of product innovation for small-molecule drugs in their ability to reach previously “undruggable” drug targets. There have…

CDMO Outlook: Small Molecules—What Lies Ahead?
By

By
Sponsored by Vetter As the industry reaches the mid-point in 2026, how are CDMOs of small-molecule drugs faring? The larger scale CDMOs with late-phase and/or commercial-scale capabilities are faring well…

A CDMO Roundtable: The Making of a Molecule: Peptide Synthesis
By

By
The blockbuster success of the GLP-1 agonists and related drugs has renewed interest in peptide-based drugs, but how is the manufacturing technology evolving? In a CDMO roundtable, industry experts share…

What Tops the Industry’s Sustainability Agenda for 2026?
By

By
As bio/pharma companies and their suppliers set and implement their sustainability strategies, what issues top the industry’s sustainability agenda? Decarbonizing, standardized reporting of value-chain emissions, and coalescing talent and technology…

2026 Outlook: CDMO Market for Injectables
By

By
Sponsored by Lonza AG In taking a 360-degree view of the CDMO market for injectables, what are the key developments from 2025 that continue to loom large in 2026? Ian…

2026: Drugs To Watch: The Year Ahead
By

By
Which bio/pharmaceuticals, slated to be launched or approved in 2026, may be potential blockbusters or are raising the innovation bar to new heights? Matthew Arnold, Principal Analyst and Content Strategist,…